<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496196</url>
  </required_header>
  <id_info>
    <org_study_id>0096-11-MMC</org_study_id>
    <nct_id>NCT01496196</nct_id>
  </id_info>
  <brief_title>The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemoptysis is defined as the expectoration of blood from respiratory tract, a spectrum that
      varies from blood-streaking of sputum to coughing up large amounts of pure blood.

      Massive hemoptysis variably defined as the expectoration of 100-600 ml over 24-h period.

      The most common site of bleeding is the tracheobronchial tree, which can be affected by
      inflammation (acute or chronic bronchitis, bronchiectasis) or by neoplasm ( bronchogenic
      carcinoma, endobronchial metastatic carcinoma, bronchial carcinoid tumor). The bronchial
      arteries, which originate either from aorta or from intercostal arteries, and are part of the
      high-pressure systemic circulation, are the source of bleeding in bronchitis or
      bronchiectasis or endo bronchial tumors.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bleeding stops</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hemoptisis</condition>
  <arm_group>
    <arm_group_label>tranexamic acid-500 mg/5 ml 3-4 times a day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tranexamic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic acid</intervention_name>
    <description>500 mg/5 ml 3-4 times a day</description>
    <arm_group_label>tranexamic acid-500 mg/5 ml 3-4 times a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic acid</intervention_name>
    <description>500 mg/5 ml 3-4 times a day</description>
    <arm_group_label>tranexamic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Hemodynamicaly stable

          -  Hemoptysis of varying etiologies

          -  Coumadin treatment will be switched to clexane or heparine

        Exclusion Criteria:

          -  Age &lt; 18

          -  Hemodinamicaly unstable

          -  Massive hemoptysis ( &gt; 200 ml / day)

          -  Renal failure: creatinine &gt; 3, renal replacement treatment

          -  Hepatic failure: bilirubin &gt; 2 mg/dl, AST &gt; 3 of upper normal limit level

          -  Coagulation disorders, INR&gt; 2.

          -  Hypesensitivity to tranexamic acid

          -  Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Shitrit, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center, Kfar Saba, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Shitrit, Dr.</last_name>
    <phone>09-7471556</phone>
    <email>Davids3@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pulmonary department, Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>972</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Shitrit, Dr.</last_name>
      <phone>09-7471556</phone>
      <email>Davids3@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>David Shitrit, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>April 12, 2015</last_update_submitted>
  <last_update_submitted_qc>April 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemoptisis</keyword>
  <keyword>bleeding</keyword>
  <keyword>tranexamic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

